Dr Adrian Harel of Medicortex conveys the urgency of developing mitigating therapeutics for the secondary and long-term damaging effects of TBI. His article makes clear that in order to ensure effectiveness, new treatment options must be multifaceted and include neuroprotective, neurorestorative and anti-inflammatory agents. Soon the day may come when brain injuries of children, seniors, athletes, service personnel, and others, will be treated in much the same way injuries in other parts of the body are currently being treated.
https://international-pharma.com/wp-content/uploads/2014/07/Current-Perspective.pdf
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
Current Perspective on TBI
